M. Boyer
The University of Sydney · 8 works · 41 citations · h-index 4
Top works
- OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
- Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)
- OA12.05 Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer
- 1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)
- 147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer
- P1.03D.09 Single Cell RNA Sequencing and Functional Monocyte Stimulation Reveals Phenotypic Predispositions to Developing Lung Cancer in Never Smokers
- 440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
- EP16.03-041 Single Cell RNA Sequencing Reveals Phenotypic Predispositions to Developing Lung Cancer in Never-Smokers